SCHEMBL6991728

SCHEMBL6991728

O=c1[nH][nH]c2c1CNC=N2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5934711 0.65
Imidazolinone SCHEMBL28158324 0.64
Imidazolinone SCHEMBL9200599 0.64
Imidazolinone SCHEMBL17493427 0.64
Imidazolinone SCHEMBL9391330 0.64
Imidazolinone SCHEMBL14994238 0.64
SCHEMBL9962978 0.56
SCHEMBL15230377 0.56
SCHEMBL17425088 0.56 ALDH1A1 (0.30)
Hydrochloric Acid SCHEMBL11451706 0.56 ALDH1A1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1151155-C 1, 5-dihydro-pyrazolo [3, 4-D ] -pyrimidone derivatives 2004-05-26 CN claimed
EP-0973774-B1 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES BAYER AG (DE) 2003-01-22 EP claimed
US-6174884-B1 CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2001-01-16 US claimed
CN-1151155-C 1, 5-dihydro-pyrazolo [3, 4-D ] -pyrimidone derivatives 2004-05-26 CN disclosed
CN-1151155-C 1, 5-dihydro-pyrazolo [3, 4-D ] -pyrimidone derivatives 2004-05-26 CN disclosed
CN-1151155-C 1, 5-dihydro-pyrazolo [3, 4-D ] -pyrimidone derivatives 2004-05-26 CN disclosed
EP-0973774-B1 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES BAYER AG (DE) 2003-01-22 EP disclosed
US-6174884-B1 CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2001-01-16 US disclosed
US-6174884-B1 CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2001-01-16 US disclosed
CN-1255133-A 1,5-dihydro-pyrazolo [3,4-D]-pyrimidinone derivatives BAYER AG (DE) 2000-05-31 CN disclosed
CN-1255133-A 1,5-dihydro-pyrazolo [3,4-D]-pyrimidinone derivatives BAYER AG (DE) 2000-05-31 CN disclosed
CN-1255133-A 1,5-dihydro-pyrazolo [3,4-D]-pyrimidinone derivatives BAYER AG (DE) 2000-05-31 CN disclosed
EP-0973774-A1 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES BAYER AG (DE) 2000-01-26 EP disclosed
WO-1998040384-A1 1,5-DIHYDRO-PYRAZOLO[3,4-D]-PYRIMIDINONE DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1998-09-17 WO disclosed